Forte Biosciences Inc reports results for the quarter ended in January - Earnings Summary

Forte Biosciences

13/05/2024 22:35

* Forte Biosciences Inc  FBRX.OQ  reported a quarterly
adjusted
loss of 16 cents​​ per share for the quarter ended in January. 
The mean expectation of two analysts for the quarter was for a
loss of 16 cents per share. Wall Street expected results to
range from -17 cents to -16 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Forte Biosciences Inc's reported EPS for the quarter was a
loss
of 16 cents​.
    * The company reported a quarterly loss of $7.42 million.
    * Forte Biosciences Inc shares had risen by 7.0% this
quarter and
lost 9.3% so far this year.

FORECAST CHANGES
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 2 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is  "buy."

Wall Street's median 12-month price target for Forte Biosciences
Inc is $2.88 
This summary was machine generated from LSEG data May 13 at
09:35 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2024      -0.16          -0.16          Met
 Dec. 31 2023      -0.28          -0.19          Beat